Novo Nordisk Rolls Out 7.2 mg Wegovy HD Nationwide and Initiates DKK 15 B Buyback
Novo Nordisk has launched Wegovy HD, its highest 7.2 mg weight-loss injection, nationwide after securing approval under the FDA’s Priority Review Voucher program last month. The company also initiated a DKK 15 billion share repurchase programme running through February 2027 to enhance capital allocation and support share value.
1. Nationwide Launch of Wegovy HD
Novo Nordisk has introduced Wegovy HD, its highest-dose 7.2 mg semaglutide injection, across all US pharmacies following FDA approval under the Priority Review Voucher program. This offering is designed to enhance weight-loss efficacy and capture demand from patients seeking higher-dose GLP-1 therapies without increasing injection frequency.
2. DKK 15 Billion Share Repurchase Programme
Effective February 4, 2026, the company initiated a 12-month share buyback authorization capped at DKK 15 billion under European Market Abuse Regulation safe-harbour rules. The board intends to strategically deploy this capital to reduce outstanding shares, support earnings per share and strengthen shareholder value through February 2027.
3. GLP-1 Demand and Industry Tailwinds
Rising GLP-1 usage has spurred concerns over hair loss and skin elasticity, with beauty retailers reporting increased interest in supportive products. Executive commentary highlights that Novo Nordisk’s obesity treatments are driving broader market growth, potentially boosting ancillary sales and expanding overall GLP-1 adoption.